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Bioflavonoids, such as quercetin, have recently emerged as a new class of chemotherapeutic drugs for the treatment of various cancer
types, but are marred by their low potency and poor selectivity. We report that a short application of low-frequency ultrasound
selectively sensitises prostate and skin cancer cells against quercetin. Pretreatment of cells with ultrasound (20kHz, 2Wcm
 2,6 0s )
selectively induced cytotoxicity in skin and prostate cancer cells, while having minimal effect on corresponding normal cell lines. About
90% of the viable skin cancer cell population was lost within 48h after ultrasound-quercetin (50mM) treatment. Ultrasound reduced
the LC50 of quercetin for skin cancer cells by almost 80-fold, while showing no effect on LC50 for nonmalignant skin cells.
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Therapeutic selectivity plays a crucial role in determining the
success of chemotherapy. Some of the current targeted therapies
attempt to localise drugs to cancer cells based on overexpression of
epidermal growth factor receptors (EGFR) (Mendelsohn and
Baselga, 2000) or angiogenesis (Carter, 2001). Antibodies, inhibi-
tors, antisense therapy and gene therapy are also among a few
strategies that have gained momentum (Guillemard and Saragovi,
2004). Many of these strategies have now reached clinical trials;
however, these methods are still limited by issues including low
potency, delivery complications, multi-drug resistance, side effects,
collateral damage (Tattersall and Clarke, 2003) or incomplete
success (Lynch et al, 2004).
In an attempt to develop a targeted chemotherapeutic strategy,
we propose the use of bioflavonoids, which are common dietary
supplements, in conjunction with low-frequency ultrasound.
Quercetin, a major bioflavonoid in human diet, has been identified
as a chemotherapeutic agent for the treatment of breast cancer
(Singhal et al, 1995; Choi et al, 2001), colon cancer (Salucci et al,
2002), ovarian cancer (Chan et al, 2003) and prostate cancer
(Knowles et al, 2000; Nakanoma et al, 2001; Kobayashi et al, 2002).
Antiproliferative action of quercetin is hypothesised to be
mediated by attenuating phosphorylation of activated hsp tran-
scription factor (hsf), shortly after its trimerisation (Nagai et al,
1995; Lee et al, 1998), thereby resulting in increased susceptibility
of hsf to proteolytic degradation and as a consequence inhibiting
all downstream events, including hsp expression (Li et al, 1999).
Since hsps are constitutively overexpressed in many tumours
(Jaattela, 1999), inhibition of hsps is an attractive chemotherapeu-
tic strategy. hsps form a complex with mutant p53 protein (mp53),
thereby prolonging the half-life of malignant mp53 and allowing
tumour cells to bypass the normal mechanism of cell cycle arrest
(Selkirk et al, 1996).
In spite of its therapeutic benefits, utilisation of quercetin in
clinical applications has been limited by low potency and poor
specificity. Additionally, it is difficult to sustain therapeutic
quercetin concentrations in blood by oral ingestion (Lamson and
Bringall, 2000).
Here, through in vitro studies, we demonstrate for the first time,
using two pairs of normal and cancer cells (human skin fibroblast
and human prostate epithelial cells), that ultrasound selectively
sensitises cancer cells against quercetin. LC50 of quercetin for skin
cancer cells is selectively decreased by almost 80-fold by a short
pretreatment with ultrasound.
MATERIALS AND METHODS
Cell culture
Normal and cancer cells derived from prostrate and skin tissues
were investigated in this study. DU145 prostate cancer cells were
provided by Dr L Wilson at UC Santa Barbara, CA, USA.
Nonmalignant prostrate normal cells (Catalog No. CRL-11609),
nonmalignant skin cells (Catalog No. CRL-7761) and skin cancer
cells (Catalog No. CRL-7762) were obtained from the American
Type Culture Collection (ATCC, Rockville, MD, USA). All cells
were grown as monolayers and were kept in a 5% CO2
environment at 371C. Cell cultures were maintained in Dulbecco’s
modified Eagle’s medium (DMEM) with glucose (1gl
 1), NaHCO3
(3.7gl
 1), L-glutamine (2mM), nonessential amino acids
(0.0815gl
 1) and 10% FBS. Antibiotic–antimycotic cocktail
(Catalog No. 15240-062, Gibco, Invitrogen Corporation, Carlsbad,
CA, USA), at a final concentration of 100Uml
 1 of penicillin,
100mgml
 1 of streptomycin and 0.25mgml
 1 of amphotericin B,
was added to all cultures. Cells were harvested at a concentration
of about 3 10
5cellsml
 1, by washing with versene (NaCl – 8gl
 1,
KCl – 0.2gl
 1, NaH2PO4 – 1.15gl
 1,K 2HPO4 – 0.2gl
 1,N a 2-
EDTA – 0.2gl
 1 in distilled water with pH adjusted to 7.2)
followed by 2–3-min digestion with trypsin/EDTA (0.25%/0.02%).
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Aliquots of 2ml cell suspension (3 10
5cellsml
 1) were plated in
12-well plates. Ultrasound was applied to cells prior to quercetin
exposure. Other sequences of ultrasound and quercetin application
were not studied and may yield different results. Ultrasound was
applied at a frequency of 20kHz and an intensity of 2Wcm
 2
(Sonics and Materials, Danbury, CT, model VCX 400). Ultrasound
intensity was determined using a hydrophone (Tezel et al, 2002).
Ultrasound was applied at room temperature for 60s by directly
immersing the transducer half-way down the meniscus in the well.
The temperature of the cell suspension was recorded to ensure that
no significant elevation of temperature (o51C) was observed. 20ml
of quercetin solution prepared in dimethyl sulphoxide (DMSO)
was immediately added after each sonication to the wells to achieve
a final quercetin concentration of 0–50mM. Cells were analysed for
viability at the end of 48h. In experiments involving multiple
exposures of ultrasound, the adhering monolayer of cells in the
wells was washed with the procedure described above. The washed
cell suspension from each well was made up to 2ml by adding
DMEM and subsequently sonicated by plating it in a new 12-well
plate. Additional exposures were performed in some experiments
at the end of 48 and 72h and cell viability assessed at the end of
96h. Cell viability prior and during experimentation was
determined using Trypan blue exclusion under a light microscope.
Gel electrophoresis and Western blots
Malignant and nonmalignant skin cells were treated with
ultrasound and quercetin (50mM) and their hsp content was
assessed using Western blots after 48h. Specifically, the culture
medium was removed after the treatment and the wells were
washed three times with PBS to remove the serum and dead cells.
The removed culture medium was mixed with PBS and centrifuged
for 10min to recover the dead cell pellet. 200ml of lysis buffer
containing 20mM Tris (pH¼7.4, Sigma), 150mM NaCl (Sigma, St
Louis, MO, USA), 1% Triton X-100 nonionic detergent buffer (ICN
Biomedicals, Aurora, OH, USA) with 1mM pepstatin, leupeptin
and PMSF (Sigma Chemicals, St Louis, MO, USA) was added to the
well and the dead cell pellet separately to obtain respective cell
lysates. The cell lysates were then centrifuged for 10min and the
supernatant protein extracts were used for electrophoresis
measurements. Electrophoresis samples were prepared on a cell
number basis by mixing the two protein extracts and using the
previously obtained cell density data, such that all the samples
contained proteins from an equal number of starting cell
population (roughly 6 10
5cells per well). Heat shock protein 72
(hsp72) mouse monoclonal IgG antibody (Catalog No: SPA-810,
Stressgen, Victoria, BC, Canada) was used to measure the
induction of inducible form of heat shock protein 70 family
(hsp70), viz., hsp72. Anti-mouse IgG horseradish peroxidase-
conjugated antibody (Amersham Pharmacia, UK) was used as
the secondary antibody. Dilutions of 1:1000 for the primary
antibody and 1:5000 for the secondary antibody were typically
used. Images were captured using X-ray films by the ECL Western
blotting detection kit (Amersham Pharmacia, UK) and quantified
by densitometry by using the software ImageQuantt TL (Amer-
sham Biosciences, UK).
RESULTS
Cytotoxic effects of quercetin and ultrasound were assessed using
two pairs of normal and cancer cell lines (human skin fibroblast
and human prostate epithelial cells). The pair of skin cells was
obtained from the same donor and differed from each other only
in terms of malignancy. Cells were incubated with quercetin (0–
50mM) with or without prior exposure to ultrasound (20kHz,
2Wcm
 2, 60s). A strong concentration-dependent cytoxicity was
observed in skin cancer cells for the combined ultrasound and
quercetin treatment (Figure 1A, closed squares), but not in
nonmalignant skin cells (Figure 1A, open squares, Po0.001 for
quercetin¼50mM). About 90% of viable population of skin cancer
cells was lost in 48h after ultrasound and quercetin (50mM)
treatment (Figure 1A, closed squares). In the absence of
ultrasound, quercetin showed no significant effect on either
malignant or nonmalignant skin cells after 48h incubation
(Figure 1A, closed circles and open circles, respectively; P40.90
for 50mM quercetin concentration). Similar results were obtained
for prostate cancer and normal cells (data not shown, Po0.05 for
ultrasound, followed by quercetin (50mM) treatment).
Enhancement in quercetin cytotoxicity towards skin cancer cells
due to ultrasound exposure (defined as the fraction of cells killed
with ultrasound exposure divided by the fraction of cells killed
without the use of ultrasound at the same quercetin concentration)
increased with increasing quercetin concentrations (Figure 1B,
closed circles; Po0.02 for 50mM quercetin concentration). Ultra-
sound had no effect on quercetin toxicity towards nonmalignant
skin cells (Figure 1B, open circles). Tumour selectivity (defined as
the number of dead cancer cells divided by number of total dead
cells; for equal number of normal and cancer cells treated) as high
as 82% was observed. Ultrasound alone had no effect on cell
viability of either type of skin cells (viability of 9675% for both
types of skin cells). The effect of ultrasound on quercetin-induced
cytotoxicity is clearly due to the synergistic activity between the
two and not due to the direct effect of ultrasound on cell viability.
The LC50 (quercetin concentration necessary to reduce cell
viability by 50%) for skin cancer cells was also significantly
reduced by ultrasound pre-exposure (Figure 2A: filled bar – skin
cancer cells, open bar – nonmalignant skin cells). In the absence of
ultrasound, LC50 of skin cancer cells was 98mM. However, a single
exposure to ultrasound for 60s reduced LC50 to about 9mM and
two further applications of ultrasound 24h apart reduced LC50 by
80-fold to about 1.2mM.L C 50 of nonmalignant skin cells was not
significantly altered (450mM in all cases). To assess the specificity
of synergy between quercetin and ultrasound, similar experiments
were performed using another drug geldanamycin (a drug known
to interfere with hsp90 cycle) and ultrasound. Geldanamycin alone
exhibited cytotoxicity consistent with prior reports (Gan et al,
1998); however, no synergistic effect with ultrasound was found.
Selective effect of quercetin and ultrasound on skin cancer cells
was accompanied by an effect on the inducible form of hsp70
(hsp72), which has long been known to confer protection to cells
under severe stress (Kiang and Tsokos, 1998) and has been
identified as a target of quercetin (Hansen et al, 1997). Skin cancer
cells exhibited higher concentrations of hsp72 (1.8-fold, Po0.05)
compared to corresponding nonmalignant cells (Figure 2B, lane 4
vs lane 1). This observation is consistent with the generally
accepted notion that cancer cells overexpress heat shock proteins
(Jaattela, 1999; Jolly and Morimoto, 2000; Nylandsted et al, 2000).
Ultrasound alone or ultrasoundþquercetin had minimal effect on
cellular hsp72 in nonmalignant skin fibroblasts (Figure 2B, 12%
decrease for ultrasound alone, P40.90, and 22% decrease for
ultrasoundþ50mM quercetin, P40.76). A combination of ultra-
sound and quercetin (50mM) induced a significant decrease in
hsp72 concentration in skin cancer cells (72% decrease, Po0.01,
Figure 2B). In the same cells, quercetin alone decreased hsp72
concentration by 31.4% (Figure 2B, lane 7) and ultrasound alone
decreased hsp72 concentration by 31.7% (Figure 2B, lane 5).
DISCUSSION
The effects reported in Figures 1 and 2 are unlikely to originate
from enhanced transport of quercetin by ultrasound. Quercetin is a
small and slightly lipophilic molecule (molecular weight¼302Da,
octanol–water partition coefficient, Ko/wB1.270.13 (Brown et al, 1998))
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sand is expected to diffuse across cell membranes at a high rate.
Intracellular quercetin concentrations are expected to be in
equilibrium with extracellular concentration even without ultra-
sound. Moreover, under the conditions used for the experiments in
this study, a moderate degree of cavitation was observed (data not
shown) and was not strong enough to induce significant
membrane permeabilisation (as judged by lack of intracellular
uptake of calcein under identical conditions), and hence incapable
of pushing quercetin into cells.
It is not clear at this stage as to how ultrasound selectively
sensitises cancer cells against quercetin. It is possible that the
selectivity originates from the effect of quercetin as well as
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Figure 1 (A) Fractional loss of viable skin cancer cells (closed squares)
and skin normal cells (open squares) when exposed to various
concentrations of quercetin after a short exposure to ultrasound
(20kHz, 2Wcm
 2, 60s). Po0.25 for 5mM quercetin concentration; and
Po0.001 for 25 and 50mM quercetin concentration. The figure also shows
fractional loss of viable skin cancer cells (closed circles) and skin normal cells
(open circles) when exposed to various concentrations of quercetin
without ultrasound exposure. P40.35 for 5mM quercetin concentration,
and P40.90 for 25 and 50mM quercetin concentration. Error bars indicate
standard deviation. For skin cancer cells exposed to quercetin alone, error
bars are shown only on one side for visual clarity. (B) Enhancement of
cytotoxicity due to ultrasound application in skin cancer (closed circles) and
skin normal cells (open circles) after incubation with quercetin at various
concentrations. Po0.30 for 5 and 25mM quercetin concentrations; Po0.02
for 50mM quercetin concentration. Each point represents the average of
three to five points. Error bars indicate standard deviation. Unpaired t-test
for unequal variance was used to calculate probability values.
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Figure 2 (A) Reduction of LC50 for skin cancer cells (filled bar) and skin
normal cells (open bars) due to application of ultrasound and quercetin.
Quercetin alone has an LC50 of about 98mM for skin cancer as well as skin
normal cells. A single application of ultrasound (20kHz, 2Wcm
 2,6 0 s )
prior to incubation with quercetin substantially decreased LC50 for skin
cancer cells to 9mM, but only moderately affected LC50 for skin normal cells
(86mM). Application of three ultrasound pulses (prior to quercetin
application, at 48h and 72h after the first application) further reduced
LC50 for skin cancer cells to 1.2mM. Application of two pulses had no
significant effect on LC50 for skin normal cells. (B) Cellular concentrations
of hsp72 in nonmalignant skin cells (first three lanes) and skin cancer cells
(last four lanes). The first lane shows hsp72 concentration in nonmalignant
skin cells prior to exposure to ultrasound or quercetin (control). The
second lane shows hsp72 concentration in nonmalignant cells exposed to
ultrasound alone. The third lane shows hsp72 concentration in non-
malignant skin cells exposed to ultrasound, followed by 50mM quercetin for
48h. The fourth lane shows control samples for skin cancer cells. hsp72
concentration in skin cancer cells is higher than that in skin normal cells. The
fifth lane represents skin cancer cells exposed to ultrasound alone (20kHz,
2Wcm
 2, 60s). The sixth lane shows hsp72 concentration in skin cancer
cells exposed to ultrasound and subsequently to 50mM quercetin for 48h.
The seventh lane represents cells exposed to 50mM quercetin alone for
48h.
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interfere with the stress response and inhibit hsp72 both at protein
and mRNA levels in certain cells (Hosokawa et al, 1990; Elia and
Santoro, 1994; Jakubowicz-Gil et al, 2002). Ultrasound, being a
mild stress, may also induce a stress response in mammalian cells.
It is possible that the interplay between the effect of ultrasound
and quercetin on hsp cycle leads to selective sensitisation of cancer
cells against ultrasound. Whether or not other mild stresses, for
example, hypoxia, yield similar results remains to be seen. Since
elevated levels of hsps are broadly associated with survival of
cancer cells (Burdon, 1987; Lasunskaia et al, 1997), chemother-
apeutic strategies that target hsps are attractive. With further
studies focused on in vivo testing and mechanistic understanding,
this technique may provide a potential treatment for the treatment
of cancer, especially skin cancer.
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